Profile data is unavailable for this security.
About the company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
- Revenue in USD (TTM)1.13bn
- Net income in USD-208.80m
- Incorporated2003
- Employees1.60k
- LocationEmergent BioSolutions Inc300 Professional DrGAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 631-3200
- Fax+1 (240) 631-3203
- Websitehttps://emergentbiosolutions.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | 247.00m | -180.81m | 391.29m | 597.00 | -- | -- | -- | 1.58 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 415.77m | 135.00 | -- | -- | -- | 7.06 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 458.70m | 147.00 | 120.18 | -- | 79.11 | 2.91 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Xeris Biopharma Holdings Inc | 187.36m | -63.11m | 460.66m | 377.00 | -- | -- | -- | 2.46 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| SIGA Technologies Inc | 173.73m | 85.71m | 462.47m | 45.00 | 5.46 | 2.73 | 5.36 | 2.66 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Theravance Biopharma Inc | 63.19m | -49.40m | 463.29m | 99.00 | -- | 2.51 | -- | 7.33 | -1.01 | -1.01 | 1.29 | 3.78 | 0.1642 | -- | 3.73 | 638,303.00 | -12.84 | -40.51 | -13.71 | -48.50 | -- | -- | -78.18 | -305.27 | -- | -- | 0.1379 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 496.53m | 240.00 | -- | -- | -- | 1.68 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Zevra Therapeutics Inc | 24.79m | -84.93m | 511.61m | 65.00 | -- | 7.31 | -- | 20.64 | -1.96 | -1.96 | 0.5825 | 1.31 | 0.150 | -- | 2.80 | 381,323.10 | -51.39 | -32.11 | -61.91 | -39.89 | 53.72 | -- | -342.63 | -128.42 | -- | -25.93 | 0.4578 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Emergent Biosolutions Inc | 1.13bn | -208.80m | 513.67m | 1.60k | -- | 1.01 | -- | 0.4564 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 651.80m | -79.00m | 525.69m | 2.52k | -- | 0.608 | -- | 0.8065 | -0.3015 | -0.3015 | 2.48 | 3.26 | 0.6062 | 4.98 | 36.38 | 259,062.80 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 593.50m | 76.00 | -- | 39.48 | -- | 258.53 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| CorMedix Inc | 12.26m | -46.15m | 604.35m | 82.00 | -- | 9.82 | -- | 49.29 | -0.8011 | -0.8011 | 0.212 | 1.01 | 0.1451 | -- | -- | 149,539.50 | -54.61 | -54.84 | -64.60 | -62.32 | 83.57 | 6.18 | -376.35 | -18,323.42 | 3.60 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Eyepoint Pharmaceuticals Inc | 45.71m | -103.57m | 609.46m | 121.00 | -- | 2.19 | -- | 13.33 | -2.01 | -2.01 | 0.9018 | 4.09 | 0.1983 | 1.05 | 106.19 | 377,793.40 | -44.94 | -40.44 | -59.48 | -47.79 | 91.48 | 83.45 | -226.57 | -186.23 | 5.45 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 26.27m | -339.45m | 638.64m | 452.00 | -- | -- | -- | 24.31 | -5.69 | -5.69 | 0.4398 | -2.74 | 0.0842 | 2.68 | -- | 58,119.47 | -108.79 | -83.26 | -126.95 | -93.77 | 83.54 | -- | -1,292.14 | -135,982.00 | 5.68 | -5.60 | 1.56 | -- | -- | -- | -1.96 | -- | -- | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Elite Pharmaceuticals Inc | 71.17m | -6.39m | 658.91m | 64.00 | -- | 13.94 | -- | 9.26 | -0.0059 | -0.0059 | 0.0677 | 0.0443 | 0.8957 | 2.68 | 4.46 | 1,112,051.00 | -8.04 | 19.07 | -10.06 | 24.29 | 44.73 | 46.63 | -8.98 | 20.77 | 2.42 | 0.75 | 0.1634 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
Data as of Nov 25 2024. Currency figures normalised to Emergent BioSolutions Inc's reporting currency: US Dollar USD
31.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.38m | 6.25% |
| Marshall Wace LLPas of 30 Sep 2024 | 2.49m | 4.62% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 2.22m | 4.12% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.91m | 3.54% |
| American Century Investment Management, Inc.as of 30 Sep 2024 | 1.73m | 3.21% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.55m | 2.88% |
| Oak Hill Advisors LPas of 30 Sep 2024 | 1.11m | 2.06% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 986.09k | 1.83% |
| Invesco Capital Management LLCas of 30 Sep 2024 | 900.91k | 1.67% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Sep 2024 | 833.18k | 1.54% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
